secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2026-07-30T20:05:11+00:00
Accession:  0001104659-26-088667
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA advisory panel votes 9-3 against Deramiocel effectiveness for DMD cardiomyopathy
--------------------------------------------------------------------------------

- FDA CTGT Advisory Committee voted 9-3 that evidence did not support Deramiocel's effectiveness for DMD cardiomyopathy; vote is non-binding.
- PDUFA target action date remains August 22, 2026; FDA will consider committee recommendation in BLA review.
- Committee's voting question addressed a narrower indication than Capricor proposed; no vote on overall benefit-risk.
- In separate discussion, committee gave directionally supportive feedback on upper limb function from HOPE-3 trial.
- CEO Linda Marbán expressed commitment to Deramiocel and confidence in HOPE-3 data; patients and families shared support.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000110465926088667/0001104659-26-088667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000110465926088667/capr-20260729x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-088667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer